drugset

drugset / Trial / NCT03052205

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205 ↗

Phase 1 Completed 54 enrolled Idera Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Timeline

Start: 2017-06-09
Primary completion: 2019-07-24
Completion: 2019-10-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tilsotolimod	Unknown	—	Other

Indications